New Head of KC-based Drug Development CRO poised for further growth and expansion

New Head of KC-based Drug Development CRO poised for further growth and expansion

Tuesday, January 28, 2020

Kansas City, KS- SEKISUI XenoTech announces the promotion of Darren Warren, PhD to President and Chief Executive Officer.
 
This promotion also marks the end of Dr. Toshinari Ohara’s tenure as CEO. Dr. Ohara will be moving back to Japan, to a position within the Drug Development Solutions Center where he worked previously. Under the leadership of both Dr. Ohara and Dr. Warren as COO, SEKISUI XenoTech has seen record growth and expects to continue the upward trend as it enters into this new era of management.
 
Dr. Ohara stated, “I am pleased to be able to turn over the company to Dr. Warren while continuing to grow the portfolio of endeavors in drug development within the SEKISUI organization. I could not leave the company in more capable hands.” Dr. Warren also added, “I am both proud and honored to take the reins from a gifted Chief Executive.  I have an optimistic view toward the future as the company is poised to provide an increasingly broad array of services and products, while consistently delivering the same level of quality, dependability, and customer service, that have become an expectation of our company.“
 
The company continues to grow in its Kansas City, KS location, employing the brightest and most capable scientists in the region. Double-digit expansion of revenue is again expected in 2020 along with other avenues of growth, including a complete website overhaul and an expanded array of consulting services. Under new leadership the organization expects to continue building expertise and establishing new footholds in the world of preclinical testing to assist pharma companies all over the world in their journeys to develop new therapeutics.
 
For over 25 years SEKISUI XenoTech has been highly regarded for its extensive selection of specialty test systems and in vitro services investigating drug metabolism and drug-drug interactions in support of safety and risk mitigation for drug developers. Now with the formation of a pool of expert internal and external consultants, clients can expect even more from their partners in nonclinical drug development.
 



About SEKISUI XenoTech
SEKISUI XenoTech, LLC is a global Contract Research Organization with unparalleled ADME / DMPK / Drug-Drug Interactions experience utilized by 98% of top pharma companies and numerous other organizations. For the past 25 years, the company has offered proven drug development expertise in evaluating drug candidates in compliance with regulatory requirement and guidance prior to entrance to market. The company offers a variety of in vitro and in vivo safety assessment studies for drug candidate evaluation, as well as an extensive selection of products for drug metabolism and pharmacokinetic research. For additional information, please refer to the company's website at www.xenotech.com or call (913) 438-7450.